Optimizing postoperative sexual function after radical prostatectomy

Therapeutic Advances in Urology

Volumn 4, Issue 6, 2012, Pages 347-365

  Tutolo, Manuela ^a   Briganti, Alberto ^a   Suardi, Nazareno ^a   Gallina, Andrea ^a   Abdollah, Firas ^a   Capitanio, Umberto ^a   Bianchi, Marco ^a   Passoni, Niccolò ^a   Nini, Alessandro ^a   Fossati, Nicola ^a   Rigatti, Patrizio ^a   Montorsi, Francesco ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

erectile function; prostate cancer; radical prostatectomy

Indexed keywords

ERYTHROPOIETIN; GROWTH FACTOR; LEVACECARNINE; MIRODENAFIL; PAPAVERINE; PENTOXIFYLLINE; PHENTOLAMINE; PHOSPHODIESTERASE V INHIBITOR; PROPIONYLCARNITINE; PROSTAGLANDIN E1; SILDENAFIL; SILDENAFIL NITRATE; TADALAFIL; VARDENAFIL;

BACKACHE; CARDIOVASCULAR DISEASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; EVENING DOSAGE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HUMAN; LAPAROSCOPIC SURGERY; MONOTHERAPY; MYALGIA; NERVE INJURY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PENILE BLOOD FLOW; PENIS ERECTION; PENIS PROSTHESIS; PENIS REHABILITATION; PRIORITY JOURNAL; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION CARE; REVIEW; ROBOTICS; SMOOTH MUSCLE RELAXATION; STEM CELL TRANSPLANTATION; SUPPOSITORY; VACUUM; VACUUM ERECTION DEVICE;

EID: 84868224147     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287212450063     Document Type: Article

References (133)

1. Abdel-Salam O.M. Baiuomy A.R. El-Shenawy S.M. Arbid M.S. (2003) The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol Res 47: 331–340.
2. Albersen M. Fandel T.M. Zhang H. Banie L. Lin G. De Ridder D. (2011) Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction. Eur Urol 59: 286–296.
3. Allaf M.E. Hoke A. Burnett A.L. (2005) Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol 174: 2060–2064.
4. Anastasiadis A.G. Salomon L. Katz R. Hoznek A. Chopin D. Abbou C.C. (2003) Radical retropubic versus laparoscopic prostatectomy: a prospective comparison of functional outcome. Urology 62: 292–297.
5. Andersson K.E. (2001) Neurophysiology/pharmacology of erection. Int J Impot Res 13(Suppl. 3): S8–S17.
6. Arai Y. Okubo K. Aoki Y. Maekawa S. Okada T. Maeda H. (1999) Patient-reported quality of life after radical prostatectomy for prostate cancer. Int J Urol 6: 78–86.
7. Armani A. Marzolla V. Rosano G.M. Fabbri A. Caprio M. (2011) Phosphodiesterase type 5 (PDE5) in the adipocyte: a novel player in fat metabolism? Trends Endocrinol Metab 22: 404–411.
8. Atkins S. Smith K.G. Loescher A.R. Boissonade F.M. Ferguson M.W. Robinson P.P. (2006) The effect of antibodies to TGF-beta1 and TGF-beta2 at a site of sciatic nerve repair. J Peripher Nerv Syst 11: 286–293.
9. Baniel J. Israilov S. Segenreich E. Livne P. M. (2001) Comparative evaluation of treatments for erectile dysfunction in patients with prostate cancer after radical retropubic prostatectomy. BJU Int 88: 58–62.
10. Barrett-Connor E. (2004) Cardiovascular risk stratification and cardiovascular risk factors associated with erectile dysfunction: assessing cardiovascular risk in men with erectile dysfunction. Clin Cardiol 27: 8–13.
11. Bianco F.J. Jr Scardino P.T. Eastham J.A. (2005) Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (‘trifecta–). Urology 66(5 Suppl.): 83–94.
12. Bischoff E. (2004) Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004; 16(Suppl. 1): S11–S114.
13. Bivalacqua T.J. Champion H.C. Usta M.F. Cellek S. Chitaley K. Webb R.C. (2004) RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci U S A 101: 9121–9126.
14. Bivalacqua T.J. Deng W. Kendirci M. Usta M.F. Robinson C. Taylor B.K. (2007) Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol 292: H1278–H1290.
15. Bivalacqua T.J. Pierorazio P.M. Su L.M. (2010) Open, laparoscopic and robotic radical prostatectomy: optimizing the surgical approach. Surg Oncol 18: 233–241.
16. Blander D.S. Sanchez-Ortiz R.F. Wein A.J. Broderick G.A. (2000) Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int J Impot Res 12: 165–168.
17. Borlaug B.A. Melenovsky V. Marhin T. Fitzgerald P. Kass D.A. (2005) Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112: 2642–2649.
18. Box G.N. Ahlering T.E. (2008) Robotic radical prostatectomy: long-term outcomes. Curr Opin Urol 18: 173–179.
19. Briganti A. Gallina A. Salonia A. Farina E. Zanni G. Rigatti P. (2005) Reliability of classification of erectile function domain of the international index of erectile function in patients affected by localized prostate cancer who are candidates for radical prostatectomy. Urology 66: 1140; author reply 1140–1141.
20. Briganti A. Montorsi F. (2006) Penile rehabilitation after radical prostatectomy. Nat Clin Pract Urol 3: 400–401.
21. Briganti A. Gallina A. Suardi N. Capitanio U. Tutolo M. Bianchi M. (2010) Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. J Sex Med 7: 2521–2531.
22. Burnett A.L. (2003) Rationale for cavernous nerve restorative therapy to preserve erectile function after radical prostatectomy. Urology 61: 491–497.
23. Burnett A.L. (2005) Erectile dysfunction following radical prostatectomy. JAMA 293: 2648–2653.
24. Burnett A.L. Aus G. Canby-Hagino E.D. Cookson M.S. D–Amico A.V. Dmochowski R.R. (2007) American Urological Association Prostate Cancer Guidelines Uptake Panel. J Urol 178: 597–601.
25. Burnett A.L. Allaf M.E. Bivalacqua T.J. (2008) Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: a retrospective analysis. J Sex Med 5: 2392–2398.
26. Burnett A.L. Goldstein I. Andersson K.E. Argiolas A. Christ G. Park K. (2010) Future sexual medicine physiological treatment targets. J Sex Med 7: 3269–3304.
27. Caretta N. Palego P. Ferlin A. Garolla A. Bettella A. Selice R. (2005) Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol 48: 326–332.
28. Carrier S. Zvara P. Nunes L. Kour N.W. Rehman J. Lue T.F. (1995) Regeneration of nitric oxide synthase-containing nerves after cavernous nerve neurotomy in the rat. J Urol 153: 1722–1727.
29. Cavallini G. Modenini F. Vitali G. Koverech A. (2005) Acetyl-L-carnitine plus propionyl-L-carnitine improve efficacy of sildenafil in treatment of erectile dysfunction after bilateral nerve-sparing radical retropubic prostatectomy. Urology 2005; 66: 1080–1085.
30. Christ G.J. (2000a) Gap junctions and ion channels: relevance to erectile dysfunction. Int J Impot Res 12(Suppl. 4): S15–S25.
31. Christ G.J. (2000b) K+ channels and gap junctions in the modulation of corporal smooth muscle tone. Drug News Perspect 13: 28–36.
32. Christ G.J. Lue T. (2004) Physiology and biochemistry of erections. Endocrine 23: 93–100.
33. Claro Jde A. de Aboim J.E. Maríngolo M. Andrade E. Aguiar W. Nogueira M. (2001) Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J 119: 135–137.
34. Coelho R.F. Rocco B. Patel M.B. Orvieto M.A. Chauhan S. Ficarra V. (2010) Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers. J Endourol 24: 2003–2015.
35. Cookson M.S. Nadig P.W. (1993) Long-term results with vacuum constriction device. J Urol 149: 290–294.
36. Cooperberg MR. Broering JM. Litwin MS. Lubeck DP. Mehta SS. Henning JM. (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004 171: 1393–1401.
37. Dean R.C. Lue T.F. (2005) Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 32: 379–395, v.
38. De Berardis G. Pellegrini F. Franciosi M. Belfiglio M. Di Nardo B. Greenfield S. (2003) Identifying patients with type 2 diabetes with a higher likelihood of erectile dysfunction: the role of the interaction between clinical and psychological factors. J Urol 169: 1422–1428.
39. Desouza C. Parulkar A. Lumpkin D. Akers D. Fonseca VA. (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25: 1336–1339.
40. Fowler F.J. Jr. Barry MJ. Lu-Yao G. Roman A. Wasson J. Wennberg J.E. (1993) Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 42: 622–629.
41. Franklin K. Goldberg RJ. Spencer F. Klein W. Budaj A. Brieger D. (2004) Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch Intern Med 164: 1457–1463.
42. Gacci M. Ierardi A. Rose AD. Tazzioli S. Scapaticci E. Filippi S. (2010) Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med 7: 234–243.
43. Goeman L. Salomon L. La De Taille A. Vordos D. Hoznek A. Yiou R. (2006) Long-term functional and oncological results after retroperitoneal laparoscopic prostatectomy according to a prospective evaluation of 550 patients. World J Urol 24: 281–288.
44. Gori T. Sicuro S. Dragoni S. Donati G. Forconi S. Parker J.D. (2005) Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 111: 742–746.
45. Gratzke C. Angulo J. Chitaley K. Dai Y.T. Kim N.N. Paick J.S. (2010) Anatomy, physiology and pathophysiology of erectile dysfunction. J Sex Med 7: 445–475.
46. Halcox J.P. Nour K.R. Zalos G. Mincemoyer R.A. Waclawiw M. Rivera C.E. (2002) The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40: 1232–1240.
47. Hall M.C. (1995) Management of erectile dysfunction after radical prostatectomy. Semin Urol Oncol 13: 215–223.
48. Hatzichristou D. Montorsi F. Buvat J. Laferriere N. Bandel T.J. Porst H. (2004) The efficacy and safety of flexible-dose vardenafil (Levitra1) in a broad population of European men. Eur Urol; 45: 634–641.
49. Hatzimouratidis K. Burnett A.L. Hatzichristou D. McCullough A.R. Montorsi F. Mulhall J.P. (2009) Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application. Eur Urol, 2009. 55(2): p. 334–47.
50. Hatzimouratidis K. Hatzichristou D. (2007) Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 2007; 51: 75–88.
51. Heidenreich A. (2008) Radical prostatectomy in 2007: oncologic control and preservation of functional integrity. Eur Urol 53: 877–879.
52. Hong E.K. Lepor H. McCullough A.R. (1999) Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). Int J Impot Res 11(Suppl. 1): S15–S22.
53. Hu J.C. Gu X. Lipsitz S.R. Barry MJ D–Amico AV Weinberg AC. (2009) Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 302: 1557–1564.
54. Jackson G. Kloner R.A. Costigan T.M. Warner M.R. Emmick J.T. (2004) Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med 1: 161–167.
55. Jarow J.P. Burnett A.L. Geringer A.M. (1999) Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 162: 722–725.
56. Jaumann M. Dettling J. Gubelt M. Zimmermann U. Gerling A. Paquet-Durand F. (2012) cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function. Nat Med 18: 252–259.
57. Joseph J.V. Vicente I. Madeb R. Erturk E. Patel H.R. (2005) Robot-assisted vs pure laparoscopic radical prostatectomy: are there any differences? BJU Int 96: 39–42.
58. Katz S.D. Balidemaj K. Homma S. Wu H. Wang J. Maybaum S. (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36: 845–851.
59. Kiefer R. Streit W.J. Toyka K.V. Kreutzberg G.W. Hartung H.P. (1995) Transforming growth factor-beta 1: a lesion-associated cytokine of the nervous system. Int J Dev Neurosci 13: 331–339.
60. Kim H. Sohn D.W. Kim S.D. Hong S.H. Suh H.J. Lee C.B. (2010) The effect of mirodenafil on the penile erection and corpus cavernosum in the rat model of cavernosal nerve injury. Int J Impot Res 22: 291–297.
61. Kimura M. Higashi Y. Hara K. Noma K. Sasaki S. Nakagawa K. (2003) PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 41: 1106–1110.
62. Köhler T.S. Pedro R. Hendlin K. Utz W. Ugarte R. Reddy P. (2007) A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int 100: 858–862.
63. Korfage I.J Hak T. de Koning H.J. Essink-Bot M.L. (2006) Patients– perceptions of the side-effects of prostate cancer treatment a qualitative interview study. Soc Sci Med 63: 911–919.
64. Krambeck A.E. DiMarco D.S. Rangel L.J. Bergstralh E.J. Myers R.P. Blute M.L. (2009) Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int 103: 448–453.
65. Kundu S.D. Roehl K.A. Eggener S.E. Antenor J.A. Han M. Catalona W.J. (2004) Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol 172: 2227–2231.
66. Lee M.C. El-Sakka A.I. Graziottin T.M. Ho H.C. Lin C.S. Lue T.F. (2002) The effect of vascular endothelial growth factor on a rat model of traumatic arteriogenic erectile dysfunction. J Urol 167: 761–767.
67. Lin G. Shindel A.W. Banie L. Ning H. Huang Y.C. Liu G. (2010) Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: Interference in a TGF-eta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 7: 1787–1797.
68. Litwin M.S. Flanders S.C. Pasta D.J. Stoddard M.L. Lubeck D.P. Henning JM. (1999) Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 54: 503–508.
69. Lowentritt B.H. Scardino P.T. Miles B.J. Orejuela F.J. Schatte E.C. Slawin K.M. (1999) Sildenafil citrate after radical retropubic prostatectomy. J Urol 162: 1614–1617.
70. Magheli A. Burnett A.L. (2009) Erectile dysfunction following prostatectomy: prevention and treatment. Nat Rev Urol 6: 415–427.
71. Marks L.S. Duda C. Dorey F.J. Macairan M.L. Santos P.B. (1999) Treatment of erectile dysfunction with sildenafil. Urology 53: 19–24.
72. Martínez-Jabaloyas J.M. Gil-Salom M. Villamón-Fort R. Pastor-Hernández F. Martínez-García R. García-Sisamón F. (2001) Prognostic factors for response to sildenafil in patients with erectile dysfunction. Eur Urol 40: 641–646; discussion 647.
73. Matthew A.G. Goldman A. Trachtenberg J. Robinson J. Horsburgh S. Currie K. (2005) Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress. J Urol 174: 2105–2110.
74. McCullough A.R. Hellstrom W.G. Wang R. Lepor H. Wagner K.R. Engel J.D. (2010) Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol 183: 2451–2456.
75. McMahon C. (2005) Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2: 415–425; discussion 425–427.
76. Melman A. Bar-Chama N. McCullough A. Davies K. Christ G. (2006) hMaxi-K gene transfer in males with erectile dysfunction: results of the first human trial. Hum Gene Ther 17: 1165–1176.
77. Menon M. Shrivastava A. Kaul S. Badani K.K. Fumo M. Bhandari M. (2007) Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol 51: 648–657; discussion 657–658.
78. Meuleman E.J. Mulders P.F. (2003) Erectile function after radical prostatectomy: a review. Eur Urol 2003; 43: 95–101; discussion 101–102.
79. Montorsi F. Guazzoni G. Strambi L.F. Da Pozzo L.F. Nava L. Barbieri L. (1997) Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol 158: 1408–1410.
80. Montorsi F. Briganti A. Salonia A. Rigatti P. Burnett A.L. (2004) Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. Eur Urol 45: 123–133.
81. Montorsi F. Brock G. Lee J. Shapiro J. Van Poppel H. Graefen M. (2008) Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 54: 924–931.
82. Moreland R.B. (1998) Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res 10: 113–120.
83. Mulhall J.P. (2009a) The role and structure of a postradical prostatectomy penile rehabilitation program. Curr Urol Rep 10: 219–225.
84. Mulhall J.P. (2009b) Defining and reporting erectile function outcomes after radical prostatectomy: challenges and misconceptions. J Urol 181: 462–471.
85. Mulhall J.P. (2009c) Exploring the potential role of neuromodulatory drugs in radical prostatectomy patients. J Androl 30: 377–383.
86. Mulhall J.P. Slovick R. Hotaling J. Aviv N. Valenzuela R. Waters W.B. (2002) Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with the recovery of erectile function. J Urol 167: 1371–1375.
87. Mulhall J.P. Parker M. Waters B.W. Flanigan R. (2010) The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 105: 37–41.
88. Mulhall J.P. Secin F.P. Guillonneau B. (2008) Artery sparing radical prostatectomy – myth or reality? J Urol 179: 827–831.
89. Nandipati K. Raina R. Agarwal A. Zippe C.D. (2006) Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res 18: 446–451.
90. Nath R.K Kwon B. Mackinnon S.E Jensen J.N Reznik S. Boutros S. (1998) Antibody to transforming growth factor beta reduces collagen production in injured peripheral nerve. Plast Reconstr Surg 102: 1100–1106; discussion 1107–1108.
91. Nehra A. Hall S.J. Basile G. Bertero E.B. Moreland R. Toselli P. (1995) Systemic sclerosis and impotence: a clinicopathological correlation. J Urol 153: 1140–1146.
92. Ogura K. Ichioka K. Terada N. Yoshimura K. Terai A. Arai Y. (2004) Role of sildenafil citrate in treatment of erectile dysfunction after radical retropubic prostatectomy. Int J Urol 11: 159–163.
93. Özden E. Öztürk B. Koşan M. Tezel G.G. Aki F.T. Gür S. (2011) Effect of sildenafil citrate on penile weight and physiology of cavernous smooth muscle in a post-radical prostatectomy model of erectile dysfunction in rats. Urology 77: 761 e1–7.
94. Padma-nathan H. Eardley I. Kloner R.A. Laties A.M. Montorsi F. (2002) A 4-year update on the safety of sildenafil citrate (Viagra). Urology 60: 67–90.
95. Padma-Nathan H. McCullough A.R. Levine L.A. Lipshultz L.I. Siegel R. Montorsi F. (2008) Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 20: 479–486.
96. Paick J.S. Ahn T.Y. Choi H.K. Chung W.S. Kim J.J. Kim S.C. (2008) Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008; 5: 2672–2680.
97. Petrovich M.S. Hsu H.Y. Gu X. Dugal P. Heller K.B. Sadun A.A. (1997) Pentoxifylline suppression of TNF-alpha mediated axonal degeneration in the rabbit optic nerve. Neurol Res 19: 551–554.
98. Qiu X. Sun C. Yu W. Lin H. Sun Z. Chen Y. (2012) Combined strategy of mesenchymal stem cells injection with vegf gene therapy for the treatment of diabetes associated erectile dysfunction. J Androl 33: 37–44.
99. Rabbani F. Stapleton A.M. Kattan M.W. Wheeler T.M. Scardino P.T. (2000) Factors predicting recovery of erections after radical prostatectomy. J Urol 164: 1929–1934.
100. Raina R. Lakin M.M. Agarwal A. Sharma R. Goyal K.K. Montague D.K. (2003) Long-term effect of sildenafil citrate on erectile dysfunction after radical prostatectomy: 3-year follow-up. Urology 62: 110–115.
101. Raina R. Lakin M.M. Agarwal A. Mascha E. Montague D.K Klein E. (2004) Efficacy and factors associated with successful outcome of sildenafil citrate use for erectile dysfunction after radical prostatectomy. Urology 63: 960–966.
102. Raina R. Agarwal A. Allamaneni S.S. Lakin M.M. Zippe C.D. (2005) Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology 65: 360–364.
103. Raina R. Agarwal A. Ausmundson S. Lakin M. Nandipati K.C. Montague D.K. (2006) Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 18: 77–81.
104. Raina R. Pahlajani G. Agarwal A. Zippe C.D. (2007) The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int 100: 1317–1321.
105. Rogers C.G. Trock B.P. Walsh P.C. (2004) Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results. Urology 64: 148–151.
106. Rosano G.M Aversa A. Vitale C. Fabbri A. Fini M. Spera G. (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47: 214–220.
107. Rozet F. Galiano M. Cathelineau X. Barret E. Cathala N. Vallancien G. (2005) Extraperitoneal laparoscopic radical prostatectomy: a prospective evaluation of 600 cases. J Urol 174: 908–911.
108. Sadovsky R. Basson R. Krychman M. Morales A.M. Schover L. Wang R. (2010) Cancer and sexual problems. J Sex Med 7: 349–373.
109. Sanda M.G. Dunn R.L. Michalski J. Sandler H.M. Northouse L. Hembroff L. (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358: 1250–1261.
110. Schover L.R. Fouladi R.T. Warneke C.L. Neese L. Klein E.A. Zippe C. (2002) Defining sexual outcomes after treatment for localized prostate carcinoma. Cancer 95: 1773–1785.
111. Shieh C.C. Coghlan M. Sullivan J.P. Gopalakrishnan M. (2000) Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52: 557–594.
112. Shimizu T. Hisasue S. Sato Y. Kato R. Kobayashi K. Tsukamoto T. (2005) Erectile dysfunction following nerve-sparing radical retropubic prostatectomy and its treatment with sildenafil. Int J Urol 12: 552–557.
113. Shindel A.W. Lin G. Ning H. Banie L. Huang Y.C. Liu G. (2010) Pentoxifylline attenuates transforming growth factor-beta1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix. J Sex Med 7: 2077–2085.
114. Stanford J.L. Feng Z. Hamilton A.S. Gilliland F.D. Stephenson RA Eley JW. (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 283: 354–360.
115. Takimoto E. Champion H.C. Li M. Belardi D. Ren S. Rodriguez E.R. (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11: 214–222.
116. Taskinen H.S. Ruohonen S. Jagodic M. Khademi M. Olsson T. Röyttä M. (2004) Distinct expression of TGF-beta1 mRNA in the endo- and epineurium after nerve injury. J Neurotrauma 21: 969–975.
117. Taylor J. Baldo O.B. Storey A. Cartledge J. Eardley I. (2009) Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 103: 1392–1395.
118. Tewari A. Srivasatava A. Menon M.; Members of the VIP Team. (2003) A prospective comparison of radical retropubic and robot-assisted prostatectomy: experience in one institution. BJU Int 92: 205–210.
119. Toda N. Ayajiki K. Okamura T. (2005) Nitric oxide and penile erectile function. Pharmacol Ther 106: 233–266.
120. Vlachopoulos C. Tsekoura D. Alexopoulos N. Panagiotakos D. Aznaouridis K. Stefanadis C. (2004) Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking induced endothelial dysfunction. Am J Hypertens 17: 1040–1044.
121. Wagner W. Bölling T. Hambruegge C. Hartlapp J. Krukemeyer M.G. (2011) Patients– satisfaction with different modalities of prostate cancer therapy – a retrospective survey among 634 patients. Anticancer Res 31: 3903–3908.
122. Walsh P.C Marschke P. Ricker D. Burnett A.L. (2000) Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. Urology 55: 58–61.
123. Walsh P.C. Donker P.J. (2002) Impotence following radical prostatectomy: insight into etiology and prevention 1982. J Urol 167: 1005–1010.
124. Walsh P.C. Epstein J.I. Lowe F.C. (1987) Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 138: 823–827.
125. Walz J. Burnett A.L. Costello A.J. Eastham J.A. Graefen M. Guillonneau B. (2010) A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol 57: 179–192.
126. Wang L. Chopp M. Szalad A. Liu Z. Bolz M. Alvarez F.M. (2011) Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice. Neuroscience 193: 399–410.
127. Wei T. Sabsovich I. Guo T.Z. Shi X. Zhao R. Li W. (2009) Pentoxifylline attenuates nociceptive sensitization and cytokine expression in a tibia fracture rat model of complex regional pain syndrome. Eur J Pain 13: 253–262.
128. Wittmann D. He C. Coelho M. Hollenbeck B. Montie J.E. Wood D.P. Jr. (2011) Patient preoperative expectations of urinary, bowel, hormonal and sexual functioning do not match actual outcomes 1 year after radical prostatectomy. J Urol 186: 494–499.
129. Yuan J. Hoang A.N. Romero C.A. Lin H. Dai Y. Wang R. (2010) Vacuum therapy in erectile dysfunction–science and clinical evidence. Int J Impot Res 22: 211–219.
130. Zabel P. Schade F.U. Schlaak M. (1993) Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 187: 447–463.
131. Zagaja G.P. Mhoon D.A. Aikens J.E. Brendler C.B. (2000) Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. Urology 56: 631–634.
132. Zippe C.D. Jhaveri F.M. Klein E.A. Kedia S. Pasqualotto F.F. Kedia A. (2000) Role of viagra after radical prostatectomy. Urology 55: 241–245.
133. Zippe C.D. Raina R. Thukral M. Lakin M.M. Klein E.A. Agarwal A. (2001) Management of erectile dysfunction following radical prostatectomy. Curr Urol Rep 2: 495–503.